Reference drug programs: Effectiveness and policy implications

Health Policy

Volumn 81, Issue 1, 2007, Pages 17-28

  Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug policy; Reference drug program; Therapeutic substitution

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DRUG COST; DRUG PROGRAM; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE;

COST CONTROL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS; PROGRAM EVALUATION; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 33847333167     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.05.001     Document Type: Article

References (62)

1. Huskamp H.A., Rosenthal M.B., Frank R.G., and Newhouse J.P. The Medicare prescription drug benefit: how will the game be played?. Health Affairs 19 (2000) 8-23
2. Stargardt T., Schreyogg J., and Busse R. Pharmaceutical reference pricing in Germany: definition of therapeutic groups price setting through regression procedure and effects. Gesundheitswesen 67 (2005) 469-478
3. Dormuth C., Burnett S., and Schneeweiss S. Predicting drug plan expenditure while planning reimbursement changes using policy simulation. Pharmacoeconomics 23 (2005) 1021-1030
4. Drug input and disposition. In: Beers M., and Berkow R. (Eds). The Merck manual of diagnosis and therapy. 17th ed. (1999), Merck & Co, Whitehouse Station, NJ [Chapter 298]
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). The Journal of the American Medical Association 2002; 288:2981-2997.
6. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Writing Group for the Women's Health Initiative Investigators: risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. The Journal of the American Medical Association 288 (2002) 321-333
7. Song F., Altman D.G., Glenny A.M., and Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal 326 (2003) 1-5
8. McAlister F., Laupacis A., Wells G., and Sackett D. Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. The Journal of American Medical Association 282 (1999) 1371-1377
9. Black N. Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal 312 (1996) 1215-1218
10. Agency for Healthcare Quality and Research. DEcIDE (Developing Evidence to Inform Decisions about Effectiveness) Network URL: http://effectivehealthcare.ahrq.gov/decide/index.cfm.
11. Schneeweiss S., and Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. Journal of Clinical Epidemiology 58 (2005) 323-337
12. Brookhart M.A., Wang P.S., Solomon D.H., and Schneeweiss S. Evaluating short-term drug effects in claims databases using physician-specific prescribing preferences as an instrumental variable. Epidemiology 17 (2006) 268-275
13. Simon G.E., Psaty B.M., Hrachovec J.B., and Mora M. Principles for evidence-based drug formulary policy. Journal of General Internal Medicine 20 (2005) 964-968
14. Grymonpre R.E., Mitenko P.A., Sitar D.S., Aoki F.Y., and Montgomery P.R. Drug-associated hospital admissions in older medical patients. Journal of the American Geriatrics Society 36 (1988) 1092-1098
15. Schneeweiss S., Hasford J., Gottler M., Hoffmann A., Riethling A.K., and Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. European Journal of Clinical Pharmacology 58 (2002) 285-291
16. Huskamp H.A., Rosenthal M.B., and Frank R.G. Newhouse JP: the Medicare prescription drug benefit: how will the game be played?. Health Affairs 19 (2000) 8-23
17. Ess S., Schneeweiss S., and Szucs T. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21 (2003) 89-103
18. Goodell S., Hoadley J., O'Brien E., and Williams C. State pharmacy assistance programs vs. medicare prescription drug plans: how do they contain rising costs? (2005), Health Care Financing & Organization, Washington, DC. http://www.hcfo.net/pdf/issue1005.pdf URL
19. Kanavos P., and Reinhardt U. Reference pricing for drugs: is it compatible with US health care?. Health Affairs 22 3 (2003) 16-30
20. MacKinnon N.J., and Kumar R. Prior authorization programs: a critical review of the literature. Journal of Managed Care Pharmacy 7 (2001) 297-302
21. Fischer MA, Cheng H, Schneeweiss S, Avorn J, Solomon DH. Prior Authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: A Policy Review. Medical Care 2006, in press.
22. Lo'pez-Casasnovas G., and Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54 (2000) 87-123
23. Giuliani G., Selke G., and Garattini L. The German experience in reference pricing. Health Policy 44 (1998) 73-85
24. Ioannides-Demos L.L., Ibrahim J.E., and McNeil J.J. Reference-based pricing schemes-Effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 20 (2002) 577-591
25. Brunt J.H., Chappell N., Maclure M., and Cassels A. Assessing the effectiveness of government and industry media campaigns on seniors' perceptions of a reference based pricing policy. Journal of Applied Gerontology 17 (1998) 276-295
26. Gurwitz J.H., Soumerai S.B., and Avorn J. Improving medication prescribing and utilization in the nursing home. Journal of the American Geriatrics Society 38 (1990) 542-552
27. Wang P.S., Schneeweiss S., Solomon D.H., and Brookhart A.M. Mortality risk in elderly users of conventional vs. atypical antipsychotic medications. The New England Journal of Medicine 393 (2005) 2335-2341
28. Morgan S. Statistics and drug utilization: are prescribing rates really that high?. Canadian Medical Association Journal 165 (2001) 1507-1508
29. Iglehart J.K. Health Policy 2001: Medicare and prescription drugs. The New England Journal of Medicine 344 (2001) 1010-1015
30. Morfitt GL Report to the reference drug program consultation panel, April 2002.
31. Office of the Auditor General. Report of the Auditor General to the house of commons. Chapter 4, Management of federal drug benefit programs. Ottawa, November 2004.
32. Dickson M., and Poullier J.P. Prescription reimbursement systems in selected European countries. In: Huttin C., and Bosanquet N. (Eds). The prescription drug market (1992), Advanced series in management, North Holland, Amsterdam
33. Tamblyn R., Laprise R., Hanley J.A., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. Journal of American Medical Association 285 (2001) 421-429
34. Soumerai S.B., Avorn J., Gortmaker S., and Ross-Degnan D. Payment restrictions for prescription drugs in Medicaid: effects on therapy, cost, and equity. The New England Journal of Medicine 317 (1987) 550-556
35. Soumerai S.B., Ross-Degnan D., Avorn J., McLaughlin T.J., and Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. The New England Journal of Medicine 325 (1991) 1072-1077
36. Soumerai S.B., Ross-Degnan D., Gortmaker S., and Avorn J. Withdrawing payment for nonsientific drug therapy. Intended and unexpected effects of a large-scale natural experiment. Journal of American Medical Association 263 (1990) 831-839
37. Schneeweiss S., Soumerai S.B., Glynn R.J., Maclure M., Dormuth C., and Walker AM. Impacts of reference pricing for ACE inhibitors on drug utilization. Journal of Canadian Medical Association 166 (2002) 737-748
38. Grootendorst P.V., Dolovich L.R., O'Brien B.J., Holbrook A.M., and Levy A.R. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Canadian Medical Association Journal 165 (2001) 1011-1019
39. Marshall J.K., Grootendorst P.V., O'Brien B.J., Dolovich L.R., Holbrook A.M., and Levy A.R. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Canadian Medical Association Journal 166 (2002) 1655-1662
40. Grootendorst P.V., Marshall J.K., Holbrook A.M., Dolovich L.R., O'brien B.J., and Levy A.R. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Service Research 40 (2005) 1297-1317
41. Schneeweiss S., Maclure M., and Soumerai S. Reference drug pricing. Canadian Medical Association Journal 167 (2002) 126-127
42. Schneeweiss S., Walker A.M., Glynn R.J., Maclure M., Dormuth C., and Soumerai S.B. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors in British Columbia. The New England Journal of Medicine 346 (2002) 822-829
43. Schneeweiss S., Maclure M., and Soumerai S.B. Prescription duration after drug copay changes in the elderly: methodological aspects. Journal of the American Geriatrics Society 166 (2002) 737-748
44. Schneeweiss S., Dormuth C., Grootendorst P., Soumerai S., and Maclure M. Net health plan savings from reference drug pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Medical Care 42 (2004) 653-660
45. Hazlet T.K., and Blough D.K. Health services utilization with reference drug pricing of histamine2 receptor antagonists in British Columbia elderly. Medical Care 40 (2002) 640-649
46. Thomas M., Mann J., and Williams S. The impact of reference pricing on clinical lipid control. New Zealand Medical Journal 111 (1998) 292-294
47. Thomas M., and Mann J. Increased thrombotic vascular events after change of statin. Lancet 352 (1998) 1830-1831
48. Weiss N., and Heckbert S.R. Thrombotic vascular events after change of statin (letter). Lancet 353 (1999) 844
49. Morgan S.G. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. Health Service Research 37 (2002) 1243-1266
50. Pharmacare of British Columbia. Pharmacare trends 2000. BC Ministry of Health Services, Victoria, BC, 2001. URL: http://www.moh.hnet.bc.ca/pharme/outgoing/PcareTrends2000.pdf.
51. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. The Journal of the American Medical Association 285 (2001) 421-429
52. Johnson R.E., Goodman M.J., Hornbrook M.C., and Eldredge M.B. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Medical Care 35 (1997) 1119-1131
53. Soumerai S.B., McLaughlin T.J., Ross-Degnan D., Casteris C.S., and Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. The New England Journal of Medicine 331 (1994) 650-655
54. Schneeweiss S., Schöffski O., and Selke G.W. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy 44 3 (1998) 253-260
55. Schwabe U, Paffrath D. Arzneimittelverordnungs-Report 2001. Springer, Berlin, 2001.
56. Schöffski O. Consequences of implementing a drug budget for office-based physicians in Germany. Pharmaceconomics 10 Suppl. 2 (1996) 37-47
57. Arzneien. Kräftiges Plus im Oktober. Ärzte Zeitung 07 12 (2001)
58. Motheral B., and Fairman K.A. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Medical Care 39 (2001) 1293-1304
59. Huskamp H.A., Deverka P.A., Epstein A.M., Epstein R.S., McGuigan K.A., and Frank R.G. The effect of incentive-based formularies on prescription-drug utilization and spending. The New England Journal of Medicine 349 (2003) 2224-2232
60. Maclure M. Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues. Milbank Quarterly 83 (2005) 131-147
61. Marshall B., Cassels A., Maclure M., and Schneeweiss S. Physician attitudes to drug cost control measures in British Columbia. Canadian Journal of Clinical Pharmacology 10 (2003) 135
62. Dormuth C., and Schneeweiss S. Rapid monitoring of adverse outcomes of drug reimbursement restrictions. Pharmacoepidemiology Drug Safety 13 (2004) S310-S311